214 related articles for article (PubMed ID: 28383205)
1. IgM myeloma: A multicenter retrospective study of 134 patients.
Castillo JJ; Jurczyszyn A; Brozova L; Crusoe E; Czepiel J; Davila J; Dispenzieri A; Eveillard M; Fiala MA; Ghobrial IM; Gozzetti A; Gustine JN; Hajek R; Hungria V; Jarkovsky J; Jayabalan D; Laubach JP; Lewicka B; Maisnar V; Manasanch EE; Moreau P; Morgan EA; Nahi H; Niesvizky R; Paba-Prada C; Pika T; Pour L; Reagan JL; Richardson PG; Shah J; Spicka I; Vij R; Waszczuk-Gajda A; Gertz MA
Am J Hematol; 2017 Aug; 92(8):746-751. PubMed ID: 28383205
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma.
Sarı M; Sarı S; Nalçacı M
Turk J Haematol; 2017 Jun; 34(2):131-136. PubMed ID: 27795224
[TBL] [Abstract][Full Text] [Related]
3. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and risk stratification in multiple myeloma.
van de Donk NW; Sonneveld P
Hematol Oncol Clin North Am; 2014 Oct; 28(5):791-813. PubMed ID: 25212883
[TBL] [Abstract][Full Text] [Related]
5. IgM k multiple myeloma with monoclonal surface immunoglobulin expression.
Laribi K; Alani M; Lemaire P
Int J Hematol; 2018 Jul; 108(1):3-4. PubMed ID: 29779080
[No Abstract] [Full Text] [Related]
6. Factors affecting outcome of patients with multiple myeloma.
Basit A; Siddiqui N; Hameed A; Muzaffar N; Athar S
J Ayub Med Coll Abbottabad; 2014; 26(3):376-9. PubMed ID: 25671952
[TBL] [Abstract][Full Text] [Related]
7. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.
Schuster SR; Rajkumar SV; Dispenzieri A; Morice W; Aspitia AM; Ansell S; Kyle R; Mikhael J
Am J Hematol; 2010 Nov; 85(11):853-5. PubMed ID: 20842638
[TBL] [Abstract][Full Text] [Related]
8. Plasmablastic IgM multiple myeloma with hypocellular bone marrow.
Arter ZL; Miles D; Mignano S; Cordaro D; Roswarski J
Ann Hematol; 2020 Apr; 99(4):895-896. PubMed ID: 32055929
[No Abstract] [Full Text] [Related]
9. Challenging diagnosis of IgM multiple myeloma.
Mahmood F; Ahmed B; Thalody V; Mehdi S
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38176750
[TBL] [Abstract][Full Text] [Related]
10. IgM myeloma: a report of four cases.
Dierlamm T; Laack E; Dierlamm J; Fiedler W; Hossfeld DK
Ann Hematol; 2002 Mar; 81(3):136-9. PubMed ID: 11904738
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
12. IgM plasma cell myeloma in the era of novel therapy: a clinicopathological study of 17 cases.
Angelova EA; Li S; Wang W; Bueso-Ramos C; Tang G; Medeiros LJ; Lin P
Hum Pathol; 2019 Feb; 84():321-334. PubMed ID: 30266252
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and laboratory features of four cases with IgM multiple myeloma].
Fan JL; Fu WJ; Shi HT; Zhou F; Yuan ZG; Zhang CY; Wei W; Ye F; Zhang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):341-4. PubMed ID: 23668209
[TBL] [Abstract][Full Text] [Related]
14. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR
Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989
[TBL] [Abstract][Full Text] [Related]
15. Defining IgM multiple myeloma.
Owen RG; Feyler S; O'Connor SJ; Bond LR; de Tute RM; Rawstron AC
Am J Hematol; 2011 Aug; 86(8):717; author reply 718-9. PubMed ID: 21761439
[No Abstract] [Full Text] [Related]
16. Exploring the Clinicopathological Parameters Affecting the Outcome in Egyptian Patients with Multiple Myeloma.
Sallam YA; Samra MA; Gaber AA
Gulf J Oncolog; 2016 Jan; 1(20):51-63. PubMed ID: 27050180
[TBL] [Abstract][Full Text] [Related]
17. IgM multiple myeloma: more on a rare and heterogeneous disease.
Cabrera Q; Chantepie S; Salaun V; Levaltier X; Troussard X; Macro M
Am J Hematol; 2011 Aug; 86(8):717-8; author reply 718-9. PubMed ID: 21630314
[No Abstract] [Full Text] [Related]
18. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.
Jurczyszyn A; Olszewska-Szopa M; Hungria V; Crusoe E; Pika T; Delforge M; Leleu X; Rasche L; Nooka AK; Druzd-Sitek A; Walewski J; Davila J; Caers J; Maisnar V; Gertz M; Gentile M; Fantl D; Mele G; Vesole DH; Yee AJ; Shustik C; Lentzsch S; Zweegman S; Gozzetti A; Skotnicki AB; Castillo JJ
Leuk Lymphoma; 2016 Sep; 57(9):2071-6. PubMed ID: 26726867
[TBL] [Abstract][Full Text] [Related]
19. Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study.
Jurczyszyn A; Gozzetti A; Gdula-Argasińska J; Czepiel J; Vij R; Fiala M; Valls DJ; Mądry K; Waszczuk-Gajda A; Grosicki S; Barchnicka A; Crusoe E; Hungria V; Gentile M; Mele G; Ksieniewicz M; Vesole DH; Castillo JJ
Ann Hematol; 2017 Oct; 96(10):1693-1698. PubMed ID: 28766002
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.
Granell M; Calvo X; Garcia-Guiñón A; Escoda L; Abella E; Martínez CM; Teixidó M; Gimenez MT; Senín A; Sanz P; Campoy D; Vicent A; Arenillas L; Rosiñol L; Sierra J; Bladé J; de Larrea CF;
Haematologica; 2017 Jun; 102(6):1099-1104. PubMed ID: 28255016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
